Drug Profile


Alternative Names: AVS-206; ICN-3142; Taribavirin hydrochloride; Viramidine

Latest Information Update: 11 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valeant Pharmaceuticals International
  • Developer Kadmon Pharmaceuticals
  • Class Antivirals; Ribonucleosides; Small molecules
  • Mechanism of Action Hepatitis C virus replication inhibitors; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 01 Nov 2012 No development reported - Phase-III for Hepatitis C in USA (PO)
  • 04 Nov 2010 Taribavirin is in active development for Hepatitis C in USA
  • 01 Nov 2010 Taribavirin licensed to Kadmon Pharmaceuticals worldwide excluding Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top